Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183474 | 0.87 | TGFBR1 (0.50) | TGFBR1NOS3NOS1NOS2MAP3K12 | |
| SCHEMBL4177460 | 0.87 | TGFBR1 (0.50) | TGFBR1NOS3NOS1NOS2MAP3K12 | |
| SCHEMBL3946284 | 0.87 | TGFBR1 (0.50) | TGFBR1NOS3NOS1NOS2MAP3K12 | |
| SCHEMBL3952724 | 0.86 | TGFBR1 (0.55) | TGFBR1MAP3K12GPR52 | |
| SCHEMBL3949333 | 0.85 | TGFBR1 (0.48) | TGFBR1MAP3K12MAPK8MAPK10 | |
| SCHEMBL3944569 | 0.84 | TGFBR1 (0.54) | TGFBR1NOS3NOS1NOS2GPR52 | |
| SCHEMBL4166207 | 0.84 | TGFBR1 (0.51) | TGFBR1SYK | |
| SCHEMBL4171178 | 0.83 | TGFBR1 (0.55) | TGFBR1GPR52BRAFKDR | |
| SCHEMBL3950263 | 0.80 | TGFBR1 (0.49) | TGFBR1NOS3NOS1NOS2SYK | |
| SCHEMBL3944990 | 0.79 | TGFBR1 (0.62) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885NOS3 859/4885NOS1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.